1.
Fig. 6: A key conclusion of this study is the specificity/preference of E2 for regulating the early PA site. While 6B appears to have an effect on polyadenylation off of the PAE site, it is hard to qualitatively assess in the current data due to possible differences in PA tail lengths that smear out the RNA in the blot. Thus these data must be presented in some quantified fashion with statistics to better support this important conclusion. 2. Fig. 6 : Can the authors rule out effects on RNA stability due to differences between the constructs in the 3'UTR? I think that this should be clearly addressed in the study. 3. Fig. 7 : These data are important to the study yet in many ways appear rather preliminary. I have five major concerns: a.
The authors state on pg. 13 that these data are reproducible yet do not present the statistics to support this claim. b.
What was the relative ratio of E2 protein to RNA in these experiments? This information is important to determine the selectivity of the effect observed and may give some clues as to the mechanistic relevance of the observation. c.
It is not clear why E2 is working on a heterologous signal (L3) -why not compare the effect of E2 on HPV pAE in these studies? If it is truly a site-specific regulator of polyadenylation, these experiments should be able to provide some evidence of that. d.
The experiments are performed using a 1-2 hr incubation -which in my experience is an awfully long time for these HeLa in vitro PA assays. Are the kinetics of PA tail addition truly being affected by E2? In other words, can the authors rule out that E2 is not, for example, stimulating deadenylation in these assays? e.
The cleavage assay in Fig. 7E is of low quality due to the high level of background smearing in the lanes. This makes it difficult in my opinion to accurately quantify and thus the numbers presented are not convincing without better quality data and some statistics. 4.
Fig. 8C/D: The authors conclude that E2 causes a potentially interesting size reduction in the PA-specific complex. Based on the mechanistic model of factor sequestration that is suggested and the demonstrated cooperativity in core PA factor assembly on RNA, I'm very surprised that the effect is not a reduction in the amount of complex. Could the size reduction be simply due to a loss of PA tails that may have been added onto the RNA substrate during the 20 minutes it was incubated in the extract for these assays? I do note in Fig. 8C that a similar size reduction due to increasing E2 protein appears to be occurring in the 'U' complex as well. 5. Fig. 8E : Does the HPV mini RNA get polyadenylated in the extract? Additional evidence needs to be provided that the shifted band labeled 'PA' is truly associated with PA factors assembling on this RNA. It's dangerous to assume in these EMSAs that complexes observed on independent RNAs are identical. 6. Fig. 9A : Three very important controls/experiments need to be addressed to allow the authors to make clear conclusions from these data. a.
Since every in vitro translated protein tested in these assays interacts with E2, a negative control is needed to rule out that the protein is not simply sticky. b.
Given that E2 has a nucleic acid binding domain, the authors must rule out that the interactions they are observing are not bridged by RNA c.
An important point that should be addressed here is whether or not you can detect these interactions in living cells by co-immunoprecipitation. d.
The authors may wish to extend this observation to see if the domains required for E2 interaction with these factors are the same domains required for the observed effects on late gene expression. 7.
Fig. 9B/C/D: Were the PA factors tested all expressed at the same relative level? It appears to me that CPSF30 seems to be significantly over-expressed relative to the others in Suppl. Fig. 4 . Also the data would be more convincing if it were presented in a quantified fashion. For example it does look as though CPSF73 may have some effect on E2 function.
Referee #2:
The E2 protein of human papillomavirus (HPV) is an established transcriptional regulator and mediator of DNA replication, and one role in the shift to late gene expression is thought to be at the level of early promoter repression. However, evidence of a direct role of E2 (or any other early proteins) in late gene activation has been lacking. Recent reports indicate that E2 may be a splicing regulator, a splicing regulator for adenovirus can induce HPV late expression, and thus E2 could influence the switch to late gene expression at the RNA level. In this manuscript, evidence is presented that E2 indeed influences the late shift at the RNA level, but the surprise is that it alters use of the early polyadenylation site, which leads to read-through into the late region. The active portion of E2 was mapped to the hinge-TAD domains. The observation that E2 also blocked in vitro polyadenylation allowed for experiments aimed at determining mechanism. It was shown that E2 binds components of the CPSF polyadenylation factor and alter polyA complex mobility, which correlated with the polyA block, and expression of CPSF30 relieved E2 suppression of pAE. The authors propose that E2 promotes late gene expression by compromising use of pAE at the level of CPSF function. This finding is significant and will be of interest to the HPV and RNA processing communities. The data in the paper are of high quality, and data in support of E2 suppressing pAE are strong. However, some of the data may be over interpreted, and alternative interpretations are possible in some instances. How specificity for the effect of E2 on pAE is achieved is not addressed but given the proposed mechanism, deserves some discussion. The manuscript could also be written in a more inclusive manner such that an audience beyond HPV and/or RNA processing can appreciate the findings.
MAJOR COMMENTS
Because it is stated in the discussion that "...E2 is not strictly required for induction of HPV late gene expression... [Stubenrauch 1998 ]", might the title more accurately be "HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation"? Fig. 1B , C, etc: Western blot expression controls seem to be missing for the expressed proteins other than E2. This is especially important for those proteins that had no effect, as a trivial explanation is that they were poorly expressed. If there is a reason that the blots can't be done, the limitations of interpreting negative data should be stated. Is it possible to quantitate the northern data? There is a somewhat cryptic reference in the discussion that the effect of E2 is 'subtle' (Pg 18), and later to 'three-to five-fold' (Pg 19).
Pg 9 top, Fig. 4 : The constructs E2N and E2C are referred to in the text, but there are no data for them in Fig. 4 . Have the northerns been quantitated? It is said that M12 "did not" activate late genes, but by eye in Fig. 4D , there appears to be a small effect. Again, are there western data to show that the proteins were actually expressed where negative results were obtained (e.g., E2H)? Unless there is a compelling reason to show that the late RNAs are translated, Figs. 4E and F are indirect assays and since the direct RNA data are presented, the reporter data could be put in supplemental data. At the RNA level, E2 and M11 look similar, yet M11 stimulates less CAT activity; is there anything to this?
Pg 10-11, Figs 4D-F: The RNA data in Figs. 4A-C make the point, and thus the reporter data in Figs. 4D-F might best go in supplemental data.
Pg 11, second section: The experiments are well executed, but I don't find the rationale for the experiments to be compelling. Regardless of the E2 story, mutation of pAE will lead to late mRNA production. It is self-evident and thus is not very informative. This part should be dropped. HuR and NS1 have known sequence-specific (U-rich for HuR) and generic (NS1) effects on polyadenylation, but it's not clear that those effects are relevant to E2; they are just alternative ways to affect pAE site use. In the absence of some better rationale, this section can be dropped also.
Pg 12, second section: Some rationale as to WHY they "...wished to test..." if E2 blocks pAL would lend some significance to the experiment. Is it because E2 might have some specificity for pAE? Because one site is weaker than the other? Is it because the effect of E2 might be general? Other alternatives? Some description of pBSpliceM is needed, since it was not introduced previously. The result that E2 has less influence on the duplicated pAL is clear, but some insight to why and what the result means is in order? Is pAL "stronger", for example? Also, PTB works well in this context, but I'm left wondering what was learned from the comparison, over and above the observation that there is a difference. Some discussion of these observations is warranted.
Pg 13 bottom -14, Fig. 8 : Considerable text and Figs. 8A-C are devoted to demonstrating that "PA" is a polyA-specific complex formed on a well-characterized L3 substrate, and might better be presented as supplemental material. Pg 14 middle: It is stated that E2 caused "a size reduction" in the polyA complex. This should more accurately be called "altered mobility" because this assay does not measure 'size'. I also don't think one can conclude that E2 "disrupted" the complex, since it is formally possible all factors are there, but that a conformation change takes place that alters mobility. This issue can be definitively addressed by RNA affinity chromatography where the substrate is pulled down, and then associated pA factors can be addressed by western blot or, more elegantly, by proteomics as was done by the Manley group recently.
Pg 15 top, Fig. 8E : PolyA complex formation is assessed with HPV pAE, but missing is a polyA assay to correlate complex formation to activity.
Pg 16 and Fig. S4B : There is an issue of specificity that needs to be explained. If NS1 blocks polyA in general through CPSF30 inhibition, why is Luc activity seen at all with pE5Luc? Wouldn't NS1 also block polyadenylation at the HPV late site too? How does NS1 discriminate between pAE and pAL? Which begs the question in Fig. 8 : How does E2 discriminate between pAE and pAL if it targets the CPSF complex indiscriminately? E2 seems quite potent in vitro, where it completely blocked polyadenylation of a strong model substrate (L3). Perhaps this could be addressed in the discussion.
Pg 17, discussion: I find the beginning of the discussion section to be off target and pitched too narrowly to the HPV aficionados, and will be somewhat confusing to, or ineffective for, a broad audience. It is a lot of E1/E2 biology considering that the manuscript does not focus on this topic (the E1 experiment in Fig. 1G notwithstanding) .
Pg 17 bottom -18: My understanding of HPV integration and cancer is that because the integration is in E2, there is no possibility of late gene expression due to the structure of the integrated genome. I don't follow the line of reasoning that culminates in the idea that loss of E2 can contribute to cancer by excluding late gene expression.
The manuscript argues that the mechanism by which E2 causes repression of pAE is by compromising CPSF30 and perhaps other CPSF components. I would like to see more discussion directed at this mechanism. In general, the manuscript would benefit from well-stated rationale and conclusion statements in numerous places that would provide greater insight to a broader audience, as is expected of EMBO as opposed to a specialty virology journal.
MINOR COMMENTS
Pg 2, abstract: the phrase "... depleting the polyadenylation complex of cellular factors" is a bit vague. Would the phrase "by preventing assembly of the CPSF complex" be more clear and direct? Pg 2, middle: The description of E2 function in DNA replication is, perhaps, too detailed. Details beyond "At cell division, E2 forms a bridge ...", while true, might be dispensable.
Pg 3, end of intro: The introduction ends quite abruptly. A synopsis of the findings is in order here, capped with a statement of significance to the HPV and RNA processing fields. Fig. 1 : L2, L1, and Mut are poorly visible in the dark shaded gene representations. Also, perhaps the font of pAE and pAL could be larger or bold to make them stand out more prominently.
Pg 6 top: Most of the experiments are done with the subgenomic pBELM construct, but a full-length version is used in Fig. 3 (text on page 8). Some rationale should be given for using pBELM in many experiments if the full-length is available; the Fig. 3 experiment was included because full-length is presumably a more relevant setting.
Pg 6, top: It is stated that "... low levels of spliced L1 ... results [from] mutational inactivation of ... splicing silencers ...". It is not intuitive why mutation of a splicing silencer downstream of SA5639 would 'decrease' splicing, and seems to be the opposite of the conclusions of Zhao et al., 2004 , that splicing to L1 increases in pBELM relative to pBEL. Pg 6, middle: It is implied that E2-induced L1 is authentic, as judged from RT-PCR (Fig. 1D) . Was the product sequenced, which would be the gold standard to support that statement? Also, loading controls are used inconsistently: a loading control for the western in 1E and the northerns in 1F and H would be appropriate.
Pg 7, second para: Well-characterized expression plasmids don't interact with E2 protein, the proteins expressed from them do. Also, the experiment is not described well, since it is not stated that the proteins are coexpressed in the presence of pBELM. Could also be more direct in describing the result: "...E1 'reduced' the ability of E2..." rather than 'substantially affected', which lacks specificity. The results are clear, but the significance is not apparent to a broad audience. Pg 13, top: "An in vitro polyadenylation assay performed in the absence of ATP..." is usually referred to as a cleavage assay; it might be useful to explain this for an audience unfamiliar with the field. In fact, it is referred to as such in the methods section. The conclusion sentence needs to be more carefully phrased; it is said that "... E2 inhibits cleavage and polyadenylation in vitro." This implies that E2 inhibits the cleavage reaction AND the polyadenylation reaction. Is this what is meant? I believe the data indicate that cleavage is blocked, and this is why polyadenylation fails to occur. If the authors wish to conclude that 'polyadenylation' is inhibited, additional experiments need to be performed.
Pg 15 bottom, and Fig. 9A : While the conclusion that Fip1 associates with E2 might be true, the exposure presented in Fig. 9A is too light to allow the reader to reach the same conclusion. Might the authors wish to speculate how E2 interacts with each CPSF component and Fip1? It would have been comforting to see a protein to which it did not interact to eliminate the possibility that the E2 portion of GST-E2 isn't simply "sticky" (or use domains of E2 to map interactions).
Referee #4:
Johansson et al. from Stefan Schwartz's lab present data and suggest in their manuscript "HPV16 E2 induces HPV-16 late gene expression by inhibiting early polyadenylation" that HPV E2 protein has direct role in induction of late mRNAs encoding for L1 and L2 proteins. The effect of E2 protein is achieved through inhibition of early polyadenylation of artificial CMV promoter directed transcript, which mimics the pre-mRNA generated from the p670 of the HPV16 genome. In fact, they demonstrate, that expression of full length or C-terminally truncated HPV16 E2 in HeLa cells interfere with polyadenylation of the transcript at the early polyadenylation site. The similar effect could be demonstrated by them in the case of analogous experiments for the HPV1 transcript or with E2 proteins of low risk and cutaneous types of HPVs. They show that co-expression of E1 protein, but not other HPV proteins (E6, E7 or L1) in HeLa cells, eliminate E2 induced inhibition of early polyadenylation. They also show that expression of Adenovirus E4orf4 in the same assay replaces E2 protein and induces similar inhibition of pre-mRNA polyadenylation at early polyA site of the HPV1. They also try to demonstrate that E2 interferes with the polyadenylation of genomic HPV transcripts by transient co-transfection of the modified HPV16 genomes carrying luciferase gene instead of late proteins and show some luciferase expression indicative of production of mRNA for late genes in C33A cells. Though expression levels of luciferase are very low and effect of E2 rather moderate. They specifically show that in their model system early polyadenylation site is more effectively inhibited than late polyadenylation site. They further suggest and try to demonstrate by in vitro experiments that bacterially produced GST-fused E2 protein and C-terminally truncated E2 block polyadenylation and that E2 targets the cellular polyadenylation complex through interaction with cellular polyadenylation factors in in vitro experiments. In conclusion, the authors of this manuscript have addressed important question in the human papillomavirus biology -how the switch for generation of transcripts from early/latent to late phase of the viral life cycle occurs. The presented data in the manuscript as well as in supplement suggest that master regulator of switch between these two phases is the E2 protein, which interacts with the cellular factors engaged into polyadenylation complex, modifies properties of this complex and modified complex is unable to function at early polyadenylation site of the HPV mRNA. The amount of generated data is remarkable and technical quality is adequate. The major criticism of the conclusions of this manuscript comes from the actual initial set-up of the experiments. The gene expression, latent viral DNA replication, amplification of viral genomes and late gene expression is very closely bound to the differentiation of the epithelial cells. In fact, three types of the cells can be used for these types of studies with viral genome -human primary keratinocytes, human immortalized keratinocytes and U2OS cells, where all phases or at least some phases of the viral life cycle could be studied. Johansson et al. have built a model system to study inhibition of the polyadenylation and use for their experiments three cell lines -HeLa, C33A and A549. Non of these cell lines is capable of supporting adequate viral gene expression or replication in the case of transfection of viral genomes into these cells. One may conclude that viral gene expression in these cells is inadequate to support viral functions for initiation of viral life cycle and it is not clear at which level -transcription, splicing, polyadenylation or translation malfunctioning of viral gene expression is taking place. Therefore, it was bold decision to take cell lines, which do not support viral functions for revealing mechanism of switch of the viral life cycle from latent to late phase, measured by generation of late transcripts. Specifically, 1)
Most of the presented data are generated in HeLa cells. HeLa cells contain several copies of HPV18 integrated subgenomic fragments, which constitutively express viral oncoproteins E6 and E7. Expression of these oncoproteins is needed for the proliferation of HeLa cells. Expression of E2 proteins of different origin (BPV1 or HPVs) in HeLa cells suppresses P105 promoter, reduces E6 and E7 level in the cells and changes many functions in the cells, including, but not limited to triggering of senesence or apoptosis due to elevation of p53 in the E2 expressing cells as only one example. Addition of E1 and E2 proteins together induces replication of the integrated HPV origin, induction of DNA damage response and obviously major changes in the functioning of gene expression in the HeLa cells. That fact perhaps explains why E1 is capable of eliminating inhibition of polyadenylation by E2 protein in HeLa cells. In analogy with this one may speculate, that thus as HPV16 E2 protein binds to the integrated HPV18 LCR and regulates HPV18 E6 and E7 oncoprotein expression and through that also modifies cellular functions, the observations in this manuscript not necessarily reflect direct effect of E2 on the polyadenylation complex. Similarly, the use of C33A and A549 cells is not adequate for these studies due to the absence of functional gene expression from the viral genome in these cells.
2)
The gene expression map of papillomaviruses indicates that E2 ORF encodes full size protein, which is transcription activator, replication activator and segregation factor, beside several other functions. However, the same ORF is used for generation of repressor forms of E2. In the case of BPV1 these are E2c and E8/E2, in the case of HPVs E8/E2 is the repressor form identified. Expression of the repressor, which forms heterodimer with the full size protein is absolutely needed for stable replication of the viral genome. It means that considerable part of the E2 protein is in the cells as heterodimer and therefore, the functioning of the homodimer is largely influenced.
In conclusion, this is important study. However, the presented data are inconclusive, because the used cell lines are not suitable for study of major switch of the viral life cycle. These cells do not support HPV genome gene expression, neither viral genome replication at any stage of the viral life cycle. The use of primary keratinocytes, immortalized human keratinocytes or U2OS cells in these experiments would result in data from the celellurar system where viral genes are transcribed and processed the way, which can reflect the changes in the processes related to viral life cycle. Alternatively, use of W12 or some other stable cell lines, which maintain episomal copies of the HPV would be much more relevant to the study the switch from latent to late phase of the viral life cycle, than HeLa, C33A or A549. Referee #1:
1. 2. Fig. 6 : As we measure the induction of the L1 mRNA by E2 or PTB, and the L1 mRNA has the same UTR in all constructs, it argues against an effect on RNA stability. Furthermore, the UTR of the "E4*" mRNAs is undoubtedly different in the various constructs, but this region is spliced out on the L1 mRNAs we monitor. We do not believe that differences in RNA stability interfere with the results. A comment to this effect has been added to p21, lines 4-5 from the bottom. b. We have used 15 pmoles of GSTE2 or GSTE2NH protein, and 50 fmoles of RNA in these experiments. This information has been added to the Materials and Methods section of the manuscript (p25, lines 4-5 from the bottom).
c. We have tried many times to perform in vitro polyadenylation assays with HPV-16 pAEencoding RNA, but the HPV pAE appears to be very poorly recognised in vitro, as we did not observe consistent and reliable signals of polyadenylation. In transfected cells, the HPV pAE is enhanced by elements located 300-800 nucleotides downstream of the pAE (÷berg J. Virol, 2003 , 2005 and Terhune J.Virol., 1999 , 2001 . Lack of these elements may explain the unsuccessful attempts to perform in vitro polyadenylation with this RNA. d. We have followed protocols described in the literature, e.g. "mRNA formation and function", Academic press 1997, in which 90 minutes incubations were described. However, incubation times ranging between 30 and 120 minutes were used by us. Although the signals of polyadenylation were weaker in 30 min assays, and not shown in the manuscript, the results with E2 were the same. The following sentence has been added to the Results section (p13, lines 13-14): "Longer incubation times yield a higher degree of polyadenylation, but the effect of E2 was seen at all time points." e. We have tried various RNA substrates in the cleavage assay (adenovirus, SV40 and HPV-16 pAE), we have used nuclear extracts from various sources and we have prepared nuclear extracts according to different protocols, but we have been unable to produce cleavage assays of better quality than the assay shown in the original manuscript. We believe that usage of semipurified polyadenylation factors will be required to improve the quality of the assay in our hands, but that would require a substantial effort. At this stage, we would therefore prefer to delete the cleavage assay, and stop at the conclusion from the in vitro polyadenylation assays that clearly demonstrate that E2 inhibits polyadenylation in vitro. We speculate in the discussion (p21, line 3 from the bottom) that this might be due to E2 blocking the cleavage reaction.
4.
Fig. 8C/D: In vitro polyadenylation assays are relatively inefficient and were performed in the presence of 2mM ATP and 20mM creatine phosphate, and at 30∞C. The gel shift assays did not contain 2mM ATP, nor 20mM creatine phosphate, and were incubated at room-temperature. We consider it unlikely that RNAs in the gel shift assays are both polyadenylated and deadenylated within the 20 min time-frame of the RNA gel shift assay. We do not believe that there is a similar effect of E2 on the U-complex in Fig. 8C . First, the Ucomplex is much smaller and if E2 had had a similar effect on the U-complex as on the PAcomplex, the effect on the migration of the U-complex should be greater. Second, there is a slight gel anomaly in the gel in Fig. 8C , which may give the impression of an effect of E2 on the smaller U-complex. However, this is not seen in Fig. 8D , nor in any other gel shift experiment that we have performed. In particular, compare the last two lanes in which GSTE2NH has a substantial effect on the PA complex whereas GSTE2HC has not (Fig. 8D) . We believe that the effect of E2 is specific for the PA complex.
5
. Fig. 8E : We have repeatedly tried the HPV pAE RNA (HPVmini) in in vitro polyadenylation assay, but we have been unable to detect polyadenylated products from the HPVmini RNA. This may be due to a less efficient recognition of the pAE than the L3 pA, perhaps due to the requirement for additional sequences downstream of the pAE for recognition of pAE (see also our answer to point 3c, above). Although the gel shift pictures of the L3 RNA and the HPVmini RNAs are remarkably similar, efforts to prove that the weak upper band observed in HPVmini RNA gels is indeed a "PA-complex" have been inconclusive. We have therefore deleted the results with the HPVmini RNA in the revised version of the manuscript, and added a comment on this on p13, lines 5-8.
6
. Fig. 9A : a. As suggested by the reviewer, a negative control has been added to Figure 9A . We show that E2 does not bind to the cellular transcription repressor CtBP.
b.
GST pull-down experiments have been performed in the absence or presence of RNAse, with similar results (to demonstrate that the protein complexes are not bridged by RNA). These results have been added to Figure 9B in the revised version of the manuscript. c. As suggested by the reviewer, results from co-immunoprecipitation experiments on E2 and CPSF30 performed in transfected cells have been included in the manuscript ( Figure 9C ). Results revealed that E2 binds specifically to CPSF30. Binding to CPSF73 could not be detected in living cells, suggesting that the GST-E2-pull-down experiments in Figure 9A , may show pull down of CPSF73 as a binding partner to CPSF30. This new data is described and discussed in the text on 16, lines 2-7. d. We have not tried E2 deletion mutants in the pull down assay.
7. The samples have been rerun in Western blotting and analysed by a new anti HA-antibody. CPSF30 and CPSF73 are expressed at similar levels (supplemental data Fig. S4 ). See also Western blot in Figure 9C . In contrast, higher levels of Fip1 are produced. However, overexpression of Fip1 does not interfere with the ability of E2 to induce late gene expression, while CPSF30 does. If CPSF73 has an effect on E2 in the transfection experiments, it is relatively minor, and it may be an indirect effect.
Referee #2: GENERAL COMMENTS:
The manuscript has been modified to be more inclusive to a broader audience, to contain fewer details on the role of E2 in DNA replication and the specificity of E2 for pAE is now discussed in greater detail.
MAJOR COMMENTS: 1). We have retitled the manuscript: "HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation" 2a). Fig. 1B , C, etc: Western blots have been added to show expression of E1 and E4, in addition to E2. We were unable to detect the E6 and E7 proteins by commercially available antibodies using Western blotting. This has been stated in the Results section. We have also added the following sentence to the Results section (p5, line 5 from the bottom): "One cannot exclude that the lack of effect of E6 and E7 on late gene expression may be due to the relatively low expression levels of E6 and E7." 4a). Pg 8, bottom. RNA extracted from C33A cells transfected with pHPV16ALuc in the absence or presence of E2 was subjected to real time quantitative PCR to detect spliced L1 mRNA. Cotransfection with E2 expression plasmid induced production of L1 mRNA, as well as luciferase that was used as a surrogate marker for L1 protein. This new data has been incorporated into the modified Figure 3 (Fig. 3D) and described in the text (p8, 11-13). 4b). The C33A cell line is a HPV negative cervical cancer cell line. We have used HeLa (HPV-18 positive) cells and C33A cells in parallel and we have never seen differences between the two in our experiments. These results also support our suggestion that E6 and E7 are not involved, since they are absent from the C33A cells. Figure 4 and this is mentioned in the text on page 8, lines 6-7 from the bottom. 5d). We would prefer to keep the CAT reporter results in Figure 4 since we have used similar reporter plasmids but with luciferase instead of CAT, to demonstrate that E2 induces HPV-16 late gene expression in primary human keratinocytes, as requested by another reviewer. 6). Pg 10-11, Figs 4E-F: We would prefer to keep the CAT reporter results in Figure 4 since we have used similar reporter plasmids but with luciferase instead of CAT, to demonstrate that E2 induces HPV-16 late gene expression in primary human keratinocytes. 7). Pg 11, second section: We were anxious to show that well-characterised inhibitors of polyadenylation, independently of the mechanism of action, would have the same effect on the reporter plasmids pBEL and pBELM as E2, thereby validating our assay. Similarly, mutational inactivation of pAE yields the same phenotype as the inhibitors of polyadenylation, and as E2. In particular, mutational inactivation of pAE in pBEL yields primarily L2 mRNA, whereas mutational inactivation of pAE in pBELM yields primarily L1. This mirrors the result with E2 overexpression and argues that E2 targets polyadenylation rather than splicing or RNA stability. Our argument is that this comparison strengthens our case that E2 inhibits HPV pAE. We would prefer to keep these results in the supplemental section of the manuscript. Additional comments have been added to the manuscript on p11, line 9, clarifying this argument. 8a). Pg 12, second section: To clarify why we wished to test E2 on the late polyA signal pAL, we have added the following sentence to the Results section (p12, lines 5-8): "Since our results indicated that E2 induced late gene expression by inhibiting the HPV-16 early polyA signal, we speculated that E2 exerted a greater inhibitory effect on pAE than on pAL, as that would cause a higher induction of late gene expression, than if E2 inhibited both polyA signals to the same extent." 8b) To introduce plasmid pBSpliceM, the following sentence has been added to the Results section (p12, lines 10-12): "pBSpliceM is a previously described plasmid that contains the early polyA signal and only two splice sites named SD3632 and SA5639 that are used exclusively to produce L1 mRNAs. This plasmid does not produce L1 mRNAs unless the pAE is deleted, or the splice sites optimised. In the pBSpliceM-derived plasmid p2xpAL, the pAE had been replaced by pAL. As pAL is efficiently used in HeLa cells, plasmid p2xpAL did not produce L1 mRNA either. " 9). Pg 13 bottom -14, Fig. 8 : We believe that it would be easier for a potential reader, to have the identification of the polyadenylation complex next to the gels in which the effect of E2 on the same complex is tested. For clarity, we would therefore prefer to keep these experiments together. 10a). Pg 14 middle: "Size reduction" has been changed to "altered mobility" (p14, first line from bottom) and "disrupted" has been changed to "conformation change" (p15, line 3), as suggested by the reviewer. 10b). RNA affinity chromatography is on our list of experiments to do to identify factors in the PA complex in the absence and presence of E2. One problem is that the specific PA complex is relatively minor in relation to the unspecific U-complex. Multiple purification steps are required just to obtain the PA-complex without the U-complex. We feel that this further analysis will form the basis of future studies and comments to this effect have been added to the Discussion on p19, line 3. 11). Pg 15 top, Fig. 8E : We have tried many times to perform in vitro polyadenylation assay with HPV-16 pAE-encoding RNA, but the HPV pAE appears to be very poorly recognised in vitro, as we did not observe consistent and reliable signals of polyadenylation. In transfected cells, the HPV pAE is enhanced by elements located 300-800-nucleotides downstream of the pAE (÷berg J. Virol, 2003 , 2005 and Terhune J.Virol., 1999 , 2001 . Lack of these elements may explain the unsuccessful attempts to perform in vitro polyadenylation with this RNA. Although the gel shift pictures of the L3 RNA and the HPVmini RNAs are remarkably similar, efforts to prove that the weak upper band observed in HPVmini RNA gels is indeed a "PA-complex" have been inconclusive. We have therefore deleted the results with the HPVmini RNA in the revised version of the manuscript, and added a comment on this on p13, lines 5-8. 12). Pg 16 and Fig. S4B : We believe that a general inhibition of polyadenylation, favours late gene expression for the following reason (and this has been added to the Discussion section of the manuscript, p18): "Since E2 targets CPSF30 that is a general polyadenylation factor, required for polyadenylation of the majority of all mRNAs in the cell, the question arises how inhibition of polyadenylation through CPSF30 can specifically inhibit pAE to cause a readthrough into the late region and produce late mRNAs that are polyadenylated at pAL, without inhibiting pAL too. The simplest explanation is that a general inhibition of polyadenylation will favour late expression for the following reason: For example, if 95% of the mRNAs are polyadenylated at pAE, and E2 causes a 2-fold reduction of early polyadenylation, early gene expression would drop from 95% to 47.5% whereas late gene expression would increase from 5% to 47.5%, a near 10-fold activation in late gene expression. However, if E2 has a general inhibitory effect on polyadenylation, it would reduce polyadenylation at pAL by a factor of 2 as well, down to 23.75%. Late gene expression would still increase from 5% to 23.75%, a near 5-fold increase. This requires that E2 is relatively inefficient in inhibiting polyadenylation, or it would be cytotoxic. In conclusion, a partial inhibitory effect of E2 on polyadenylation could cause a significant increase in HPV late gene expression, while simultaneously allowing production of mRNAs that are polyadenylated at pAE, which is what is seen at the late stage in the HPV life cycle. In contrast, influenza virus NS1 is a relatively potent inhibitor of polyadenylation that shuts down host cell polyadenylation in order to favour influenza virus mRNA utilisation and to inhibit interferon production during the short influenza virus replication cycle. Therefore, to activate HPV-16 late gene expression by NS1 plasmid transfection, 10-20-fold lower concentration of NS1 plasmid than E2 plasmid was used in transfections. We speculate that E2 is a relatively weak inhibitor of polyadenylation that allows production of early mRNAs, but at a reduced level, while at the same time causing a significant increase in late gene expression." Although we find a preference for inhibition of pAE over pAL by E2, as described in Fig. 6 , the E2 protein does not shut off pAE. 13). Pg 17, discussion: The beginning of the Discussion section has been shortened and rephrased to be more to the point. 14). Pg 17 bottom -18: This section of the Discussion has been deleted in the revised version of the manuscript. 15). We have added a discussion on the mechanism of inhibition of polyadenylation, and we have better formulated rationale and conclusion statements at various places in the manuscript.
MINOR COMMENTS M1). Pg 2, abstract: The sentence has been rephrased to "by preventing the assembly of the CPSF complex", as suggested by the reviewer. M2). Pg 2, middle: The Introduction has been modified to contain fewer HPV details on HPV replication M3). Pg 3, end of intro: The following synopsis has been added to the end of the Introduction section: We show that the HPV E2 protein regulates HPV late gene expression. High levels of HPV E2 induce HPV late gene expression by inhibiting polyadenylation at the early polyA signal on the viral genome. E2 interacts with the cellular polyadenylation factor CPSF30, thereby preventing assembly of the CPSF complex at the polyA signal. This causes a read-through into the late region of the viral genome, resulting in the production of late HPV mRNAs encoding the viral structural proteins L1 and L2. M4). Fig. 1: The quality of the figures has been improved, as suggested by the reviewers. M5). Pg 6 top: Many viral proteins are pleiotropic and E2 is no exception. As stated in the introduction, it participates in replication of the HPV genome, it is required for partitioning of the HPV genome during cell division and it inhibits the early HPV promoter. To study the effect of E2 on late gene expression, we used the pBEL constructs, which lack the HPV early promoter and origin of replication through which the other effects of E2 are mediated. To clarify this, we have added the following sentence to the Results section (p6, lines 3-5): "Since E2 functioned on pBEL plasmids that lack the LCR, E2 acted independently of E2 binding sites located in the LCR. " M6). Pg 6, top: The sentence has been deleted and replaced by one sentence stating "This plasmid produces high levels of early mRNAs, primarily E4 mRNAs upon transfection of HeLa cells". (p5, lines 5-6).
M7a). Pg 6, middle: The RT-PCR products were cloned and sequenced. This has been added to the Results section (p5, lines 10-12). M7b). Loading controls for Westerns and Northerns in Fig. 1 have been added.   M8 ). Pg 7, second para: 1/ The sentence with "....well-characterised.." has been corrected. 2/ It is now stated that proteins are coexpressed in the presence of pBELM. 3/"Substantially affected" has been changed to "reduced". 4/The following sentence has been added to explain the significance to a wider audience (p6, lines 5-8 from bottom): "As E1 and E2 are coexpressed during the HPV-16 infection, one may speculate that a high E1/E2 ratio may prevent induction of late gene expression by E2 and favour replication of the HPV genome, whereas a low E1/E2 ratio may favour induction of HPV late gene expression by E2." M9). Fig. 2D , the following sentence has been added to the Figure legend 2D : "Arrow points to the band that represents cDNA synthesised from mRNAs that are polyadenylated at HPV-1 pAE. " M11) Fig. 3 vs Fig. 1 : Yes, the increase in cytoplasmic L1 mRNA (Fig. 1) is matched by the increase in luciferase protein levels (Fig. 3) . Fig. 4B : The schematic drawing of pBELM has been deleted from Fig 4B, as it is shown in Fig. 1A . However, reporter plasmids pBELCAT and pBELLuc are shown in Fig. 4E. M13) Pg 10, second para: "Previous results..." has been changed to 'Data shown above'. M14) Pg 10 middle and Figs. 5B and C: 1/ Fig 5B and C shows the same exposure of the same gel, but a number of samples in between have been deleted, so the gel was cut in two, but it does not affect the conclusions of the results. 2/The quantified effects of E2 on the CAT plasmids were 3.1 and 3.7 fold and have been added to Figure 5B . 3/We did not try the HPV element in the antisense orientation. 4/ We have added results from a 3í-RACE experiment performed on RNA from cells transfected with the CAT plasmid to show that the pAE on these plasmids is used in the transfected cells. The 3í-RACE gel is shown in Fig. 5C . The 3í-RACE products were cloned and sequenced to confirm that the 3í-RACE products represent mRNAs that are polyadenylated at pAE. This new data is shown in the modified Figure 5C and described in the text on p10, lines 14-15. M15). Pg 12, bottom, and Fig. 7C /D: 1/The in vitro polyA substrate is now referred to as "RNA" throughout the manuscript. 2/The text that links panel B with L3 has been corrected to L3short. 3/As part of this project we tried various RNAs in the in vitro polyadenylation assays in an effort to obtain more efficient in vitro polyadenylation. One strategy was to use a shorter version of the L3 RNA named L3short, but no differences between L3 and L3short were seen. M16). Pg 13, top: The gel from the cleavage assay has been deleted. The text has been rephrased (p21, lines 1-3 from bottom): "We speculate that polyadenylation fails to occur because E2 blocks cleavage." M17). Pg 15 bottom, and Fig. 9A : 1/Since the Fip1 pull down gel in Fig. 9A is too weak to reproduce, it has been deleted. We believe that polyadenylation factors in the reticulocyte lysates might form complexes with the in vitro translated products and that this may result in pull downs of entire protein complexes, i.e. polyadenylation complexes. 2/A negative control for the pull-down assay has been added to Fig. 9A , as requested. GSTE2 does not bind to the cellular transcription repressor CtBP.
M12)
Referee #4: 1) Keratinocytes versus cancer cell lines. As stated by the reviewer, we have used one HPV positive (HeLa) and one HPV negative (C33A) cervical cancer cell line, as well as a lung cancer cell line (A549). These cells are in many aspects different from human primary keratinocytes targeted by HPV. We have therefore reproduced key experiments in primary human keratinocytes, as these are the target cells of an HPV infection. Induction of HPV-16 late gene expression by E2 was overall higher in primary human keratinocytes than in the cancer cell lines. We believe that the experiments performed in keratinocytes have confirmed and further strengthened the results obtained in HeLa, C33A and A549 cell lines. The conclusions of the experiments performed in human primary keratinocytes are the same as those drawn from experiments performed in HeLa, C33A or A549 cell lines. Specifically, we transfected the two pBEL-and pBELM-derived plasmids pBELLuc and pBELMLuc, into human primary keratinocytes, with or without E2. The pBEL and pBELM were used in the majority of all transfection experiments, and are key plasmids in this manuscript. High levels of luciferase were induced by E2 in the transfected human primary keratinocytes, confirming the results obtained in transfections of C33A and HeLa cells (Fig 4H, left and right panel) . The fold induction seen with E2 was higher in human primary keratinocytes than in cancer cell lines. Analysis of E2 mutants in human primary keratinocytes confirmed that E2 and E2NH induced high levels of late gene expression, whereas E2HC did not. A difference repeatedly seen with the E2 mutants in the primary human keratinocytes, was that a higher induction of late gene expression was obtained with E2NH than with full E2. This new data is now shown in the modified Figure 4H and is described in the text on page 9, lines 13-20. The conclusions from the experiments performed with the HeLa, C33A or A549 cancer cells were supported by the results obtained with human primary keratinocytes.
We also analysed plasmid pE5Luc, in which only a short HPV-16 sequence encompassing the HPV-16 pAE has been inserted upstream of the luciferase reporter gene (Fig 5F, right panel) . The purpose was to confirm that this short region of the HPV-16 genome containing the pAE, was sufficient to obtain an induction of downstream genes by E2 also in human primary keratinocytes. This pE5Luc plasmid was transfected into human primary keratinocytes in the absence or presence of E2 plasmid and luciferase levels were monitored as described. Similarly to the results obtained with HeLa cells, full-length E2 and E2NH induced luciferase expression, while E2HC did not. Similarly to the pBEL-and pBELM-derived plasmids, E2 and E2NH showed a higher level of induction in human primary keratinocytes than in cancer cells. In addition, the E2NH induced higher levels of luciferase than the full length E2 protein. This new data is now shown in the modified Figure 5F and is described in the text on page 11, lines 1-4. We concluded that E2 induced HPV-16 late gene expression in human primary keratinocytes and in human cervical cancer cells, and that the induction levels was higher in human primary keratinocytes than in cancer cells.
2) The E8 repressor and its heterodimerisation with E2. We have used E2 cDNAs for expression of the various E2 proteins and so the alternatively spliced E2 variant cannot be made from our E2 expression plasmids. In addition, we have previously performed a thorough cDNA mapping of the pBEL and pBELM reporter plasmids and we cannot detect usage of splice site SD1302 in these plasmids (Zhao, X. et al., 2005. J. Virol., 79:4270-4288) , and usage of this splice site is required for production of the E8 repressor. We can exclude that the E8 repressor is needed for induction of late mRNAs from pBEL and pBELM reporter plasmids.
However, it would be interesting to investigate if the repressor forms of E2 are involved in the regulation of HPV late gene expression from the full HPV-16 genome, as both proteins would be expressed in HPV-16 infected cells.
We show that overexpression of E1 prevents E2 from inducing late gene expression. It would also be of great interest to cotransfect E2 and E8 expression plasmids with pBEL or pBELM reporter plasmids to determine if E8 affects the ability of E2 to induce late gene expression in this experimental system. Coexpression of E8 and E2, would presumably give rise to heterodimers in the transfected cells, and the effect of E8 on the ability of E2 to induce HPV-16 late gene expression could be determined. Comments to this effect have been added to the Discussion (p21, lines 12-14): "Formation of heterodimers between E2 and E8 may also affect the ability of E2 to induce late gene expression". References to E2-E8 have been added to the revised manuscript. We believe that it would be interesting continuation of this project, but that it is beyond the scope of this manuscript. Thank you for the submission of your revised manuscript to The EMBO Journal. It has been sent back to three of the original reviewers, who now consider that their major concerns have been properly addressed and your manuscript is almost ready for publication.
Nevertheless, as you will see below, referees still point out to some issues that need your attention before your manuscript can be accepted. Although referees #1 and #2 suggest changes mostly addressable by further discussion, I would like to particularly draw your attention to the suggestion of referee #4 of further supporting the physiological relevance of your study by including analyses of polyadenylation in transcripts from the HPV genome upon E2 overexpression.
Browsing through the manuscript myself I have noticed that the statistical analysis of the results is not properly described. As a guide, statistical analyses must be described either in the Materials and Methods section or in the legend of the figure to which they apply and will include a definition of the error bars used and the number of independent experiments performed. If the number of independent experiments is less than three, use of error bars is not appropriate and one representative experiment should be provided, clearly indicating this fact. Along these lines, albeit not absolutely necessary, we recommend the use of statistical significance analysis tools to further strengthen the interpretation of the results.
I would also like to mention that we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Although optional at the moment, would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels presented? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this initiative do not hesitate to contact me.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.
Thank you for the opportunity to consider your work for publication. I am looking forward to seeing the revised, final version of your manuscript.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORTS:
Referee #1:
I find the revised manuscript to be much improved over the original version. However three points still remain that were either explicit or implicitly part of the original critiques that I believe require additional clarification:
1. Maybe I'm missing something, but its still not clear to me why the E2 protein is acting on the adenovirus L3 poly(A) signal in vitro when the authors present fairly good data in Fig. 5 that the protein is selective in its inhibitory activity. Is E2 a specific inhibitor or isn't it? I believe that this needs to be clearly addressed for the EMBO readership. 2. Fig. 7C : The authors conclude on page 13 that "The results revealed that E2 inhibited in vitro polyadenylation of the L3short RNA substrate in a dose-dependent manner" -yet there is no statistically significant difference in the levels of inhibition observed over the range of protein concentrations used. Therefore I believe this is an overstatement of the results that should be either toned down or better supported with new data. 3. Fig. 7D : The authors conclude on page 13 that "The inhibitory activity of E2 on polyadenylation was located primarily in the E2NH fragment (Fig. 7D) , while E2HC displayed very low inhibitory activity (Fig. 7D) ". However the quantification of the data presented in the graph clearly show that there is no statistically significance difference of either protein fragment in terms of inhibitory activity. Therefore I believe this is an overstatement of the results that should be either toned down or better supported with new data. 4. Fig. 8C : Is the altered mobility of the PA complex observed when GSTE2 is added really an 'altered conformation' as concluded by the authors? From the data provided, I don't see how you can be sure that the PA factors are still even part of the complex. For example, the band may simply represent GSTE2 simply binding the RNA and shifting it on its own. Thus I believe that these data may be over-interpreted.
The authors are to be commended for the substantial work involved in addressing the concerns of all reviewers.
Major Comment: Pg 15, bottom, and 16 top: It is stated that says GST-E2 interacted less well than the E1 protein (Fig.  9A) . I see no data for E1.
Minor Comments: Pg 11, second section: The "reasoning" sentence needs grammatical attention. I still don't think this line of experimentation adds much and should be shortened or incorporated into another section.
Pg 15, top: I suggested "conformation change" as one reason for a mobility change. Perhaps simply saying that E2 "altered" the complex (rather than a conformational change) would cover all possibilities.
Pg 16 bottom, and Fig. S4A : The rationale is that over-expression of pay factors may reverse the E2 effect. The data in S4A show that recombinant protein is expressed, but there are no data showing the extent to which (or if) they are over-expressed. Negative results are uninformative without knowing that the proteins were actually over-expressed.
Referee #4:
This manuscript provides evidence that HPV master regulator of gene expression -E2 protein, is involved into induction of late transcripts encoding for late proteins by suppression of polyadenylation at early polyadenylation site of HPV. In the revised manuscript they provide new data in human primary keratonocytes, where they confirm the major findings observed in HeLa, C33A and lung cancer cell lines. The provided data remove concerns related to the use of cell lines carrying HPV18 subgenomic sequences expressing E6 and E7 proteins, which may interfere with E2 functions. In majority of cases authors have studied suppression of early polyadenylation site and generation of late transcripts from the transcripts generated from the CMV promoters. In the case if E2 protein indeed is capable of suppression of early polyadenylation this should be seen also from the transcripts of the HPV genome in W12 cells or some other established cell lines upon E2 overexpression. Referee #1:
1. Fig. 5 : We believe that E2 has a general inhibitory effect on polyadenylation, but as the effect is relatively small, the consequences are particularly apparent on mRNAs that are alternatively polyadenylated. On these mRNAs, a relatively low inhibition of the upstream polyadenylation site causes a significant increase in expression of the downstream genes, even if the downstream polyA signal is inhibited to a low extent as well (this has been discussed at p18, first section of the Discussion). However, it appears that the HPV-16 early polyA signal pAE is more sensitive to E2 than pAL, but we will have to investigate the effect of E2 on unrelated mRNAs that are alternatively polyadenylated to determine how specific E2 is. To clarify this, the following sentence has been added to the Discussion section, p18: "Although HPV-16 pAE appears to be more sensitive to E2 than pAL, the inhibition of the adenovirus L3 polyA signal in vitro and the interactions of E2 with general polyadenylation factors, argue for a general, but relatively low inhibitory effect on polyadenylation by E2.".
2.
Fig. 7C, page 13: "...in a dose dependent manner" has been deleted.
3. Fig. 7D , page 13: The sentence has been rephrased to "The full E2 protein appeared to inhibit in vitro polyadenylation to a greater extent than E2NH and E2HC, but the difference was not significant (Fig. 7D) ." 4. Fig. 8C : "altered conformation" has been changed to "altered complex". We do not believe that the altered complex represents a GSTE2-RNA complex without polyadenylation factors, since the antibody against CstF-64 caused a supershift also of the GSTE2-altered complex (data not shown). We believe that the complex is an altered polyadenylation complex, but we have not been able to elucidate its composition.
MAJOR COMMENT: Pg 15, bottom and 16 top). The sentence has been corrected and rephrased to: "GSTE2 interacted less well with the polyadenylation factors than with HPV-16 E1 (Fig. 9A) ".
